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Background: Tuberculosis is one of the leading causes of mortality among infectious diseases
worldwide.  For effective tuberculosis control, it is a pre-requisite to detect the cases as early
as  possible, and to ensure that the tuberculosis patients complete their treatment and get
cured. However, in many resource-constrained settings treatment outcome for tuberculosis
has  not been satisfactory.
Objective:  The aim of the study was to assess the treatment outcome of tuberculosis patients
and investigate the association of demographic and clinical factors with treatment success
of  patients enrolled in Directly Observed Treatment Short Course program in government
owned  health centers over the course of ﬁve consecutive years in Addis Ababa, Ethiopia.
Methods: A register based historical cohort study covering the period of July 2004 to June
2009  was conducted to determine the treatment outcome of Directly Observed Treatment
Short  Course in government owned health centers in Addis Ababa. Sex and age of tuber-
culosis  patients, health center at which the patient was treated, year of treatment, type of
tuberculosis for which the patient was treated, type of treatment offered to the patient,
follow-up  status and documented treatment outcome were extracted from the Directly
Observed  Treatment Short Course clinics of three randomly selected health centers.
Result: Records of 6450 registered tuberculosis patients (n = 3147 males and 3433 females)
were  included in this document review. Of these patients 18.1% were reported as being
cured,  64.6% were documented as treatment completed, 3.7% died during follow-up, 5.1%
were reported as defaulters, 0.4% were documented as treatment failure and 8.2% were
transferred  out to another health institution. Treatment center and year of enrollment were
signiﬁcantly  associated with treatment success.
Conclusion: Year of enrollment and treatment center were signiﬁcantly associated with treat-
ment success. Although the overall treatment success obtained in this study is in line withthe  World Health Organiza
supportive  supervision du
the observed difference in
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Introduction
Tuberculosis (TB) is a major public health problem throughout
the  world.1 According to the 2010 World Health Organiza-
tion  (WHO) Global Health Report there were  an estimated 9.4
million incident cases of TB globally.1 The target set within
the  context of the Millennium Development Goal (MDGs) is
to halt and reverse the incidence of TB by 2015.2 For effec-
tive  TB control it is very important to detect the disease as
early  as possible and to ensure that those diagnosed complete
their  treatment and get cured.3 Over 95% of new TB cases and
deaths  occur in low and middle-income countries.4 The high-
est  incidence of TB and the highest number of deaths due to
TB  occur in Asia and sub-Saharan Africa.5 The case fatality
rate  has exceeded 50% in some African countries where HIV
infection  rates are high.5,6
In Ethiopia, a standardized TB prevention and control
program incorporating Directly Observed Treatment, Short
Course  (DOTS) was  started as a pilot in 1992, at Arsi zone in
Oromia  region.7 Then DOTS strategy has been subsequently
scaled up and implemented at a national level. Currently,
the  DOTS geographic coverage has reached 90%, whereas
the  DOTS health facility coverage is 75%.7 According to 2007
WHO’s  estimates the incidence of TB of all forms and smear-
positive  TB in Ethiopia stand at 341 and 152 per 100,000
population, respectively.7
Even where free medication is available, many  patients are
not  successfully treated for TB.8,9 Incomplete treatment may
result  in an extended period of infection, TB resistance to
treatment,  and lead to increased morbidity and mortality.10
For the year 2005, the WHO  target for treatment success was
85%.2,11 Ideally, treatment outcome in all patients should be
routinely  monitored by the epidemiological surveillance sys-
tem. So far, very few studies have documented treatment
outcomes of DOTS in Ethiopia.12–17 The limitation is that pre-
vious  research focused on reports collected from Sub-city
health  ofﬁces of the city and subsequently reported to the Fed-
eral  Ministry of Health, focusing on hospitals. Our research
used  TB patient record register data in the health centers to
determine  the factors for treatment success. The aim of the
study  was  to assess the treatment outcome of TB patients
and  assess the association of demographic and clinical fac-
tors  with treatment success of patients enrolled in Directly
Observed Treatment Short Course (DOTS) program in govern-
ment  owned health centers over the course of ﬁve consecutive
years  in Addis Ababa, Ethiopia.
Methods
Study  setting  and  context
Data for this historical cohort study were  extracted from the
documentation of government health care settings in Addis
Ababa  between December 2009 and March 2010. Addis Ababa
is  the capital city of Ethiopia. In 2007, Addis Ababa had an esti-
mated  population of 2.74 million.18 Administratively, the city
is  divided into 10 Sub-cities which are in turn divided into 99
kebeles  (the smallest government administrative units). The 1 3;1  7(5):521–528
health  service delivering institutions in the city comprise 41
hospitals,  169 higher clinics, 146 private medium clinics, and
31  health centers. With the objective of increasing accessibility
DOTS  program is currently implemented in all health centers
in  the city.19
Study  design  and  selection  of  health  centers
Health service delivery institution-based historical cohort
study  was conducted in Addis Ababa between December 2009
and  March 2010. The objective was to investigate treatment
outcomes among TB patients registered in DOTS program.
Study  participants were all TB patients registered from July
2004  to June 2009 in three randomly selected health centers’
DOTS  clinic in Addis Ababa. The required information was
extracted  from TB patients who received care at Teklehay-
manot, Selam and Kolfe Heath Centers.
Deﬁnition  of  types  of  TB  and  treatment  outcome
The registration documents of the DOTS clinic in each heath
center  contains information about TB patients’ age, sex,
address,  weight, type of TB, Acid-Fast Bacilli (AFB) smear result
at  baseline, 2nd, 5th and 7th month after treatment initia-
tion,  treatment regimen used to treat each patient, date at
which  treatment was  started, date at which treatment was
stopped,  and treatment outcome. According to the standard
deﬁnitions of the National Tuberculosis and Leprosy control
Program  guideline of Ethiopia (NLCP),7 the following deﬁni-
tions  were used for treatment outcome: (a) cured if patients
have  ﬁnished treatment with negative bacteriological result
at  the end of treatment, (b) treatment completed if patients
have  ﬁnished treatment, but without bacteriological result at
the end of treatment, (c) treatment failure if a pulmonary TB
patient  was smear-positive at ﬁve month follow-up despite
correct  intake of medication, (d) defaulter if the patient inter-
rupted  treatment for two consecutive months or more  than
two  months after registration, (e) died if the patient died from
any  cause during the course of treatment, (f) transferred out if
treatment result is unknown due to transfer out to another
health  facility, and (g) successfully treated if patients were
declared  “cured” and “completed” treatment as per the pro-
tocol.
Three  types of TB were  considered in this study. The
ﬁrst  type was  smear-positive pulmonary TB (PTB+) and it
was  identiﬁed if a patient had at least two initial sputum
smear examinations positive for AFB by direct microscopy,
or  one initial smear-positive examination for AFB by direct
microscopy and a positive culture, or a patient has one initial
smear-positive examination for AFB by direct microscope and
radiographic  abnormalities consistent with active TB as deter-
mined  by a clinician. The second type was smear-negative
pulmonary TB (PTB−) and it was  characterized by a patient
having  (1) symptoms suggestive of TB with at least three ini-
tial  smear-negative examinations for AFB by direct microscopy
and  no response to a course of broad-spectrum antibiotics; (2)
three smear-negative examinations by direct microscopy, and
radiological  abnormalities consistent with pulmonary tuber-
culosis,  and decision by a clinician to treat with a full course of
anti-tuberculosis; or (3) a diagnosis based on a positive culture
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or Mycobacterium tuberculosis after three initial smear-negative
xaminations by direct microscopy. The third type was  extra-
ulmonary  TB (EPTB). In this case TB occurs in organs other
han  the lungs, proven by one positive-culture from specimens
f  an extra-pulmonary site or histo-pathological evidence
rom  a biopsy, or TB based on strong clinical evidence con-
istent  with active EPTB and the decision by a physician to
reat  with a full course of anti-TB therapy.
ata  collection  procedures  and  quality  assurance
ata were extracted from the registers of the selected health
enters  using a structured data sheet specially designed for
his  study. Data extraction was  conducted by nurse/health
fﬁcers working at the TB clinic of the selected health cen-
ers.  Before embarking on the data collection process, all data
ollectors  attended a one-day training provided by the prin-
ipal  investigator on how to ﬁll the structured data collection
heet.  To ensure data quality, the following measures were
aken:  (a) one-day training was  given for data collectors before
he  start of data collection, (b) the overall activities of data
xtraction were  monitored by the principal investigator, and
here  was  strict supervision during data collection, (c) all com-
leted  datasets were  examined by the principal investigator
or  completeness during data collection, and (d) from the data
xtracted  from each health center, 5% of the sample was ran-
omly  selected and validated against the registration book by
he principal investigator.
ain  outcome  and  pre-speciﬁed  explanatory  factors
he main outcome of interest was  treatment success of all TB
atients.  Study participants were categorized as having suc-
essful  treatment if their record showed that they were cured
r  they had completed treatment. Otherwise, they were cat-
gorized  as treatment not successful (i.e. the record showed
hat  the patient was  either treatment failure, defaulter, died,
r  transferred out). The pre-speciﬁed independent variables
or  treatment success were  patients’ age, sex, type of TB
smear-positive pulmonary TB, smear-negative pulmonary TB,
xtra-pulmonary TB), patient category at the start of treat-
ent  (Category I: new sputum smear-positive, seriously ill
ew  sputum smear-negative, new EPTB, and others; Category
I:  relapse, failure and return after interruption; Category III:
ew  sputum smear-negative, not seriously ill new EPTB, not
eriously  ill; Category IV: chronic TB patients deﬁned as smear-
ositive  pulmonary TB patients who  had previously received
 supervised re-treatment regimen. Transfer-in: TB patients
eferred  in from other health service delivery institutions) and
FB  smear-positive pulmonary TB patients result at selected
ollow-up  time points (i.e. at baseline, 2 month, 5 month, and
 months).
ata  management  and  statistical  analysis
he quantitative data extracted from the registration book of
atients  registered in DOTS program were  checked for com-
leteness  and consistency by the principal investigator. Data
ntry  and descriptive analysis were carried out using SPSS ver-
ion 16.0 for Windows (SPSS, Chicago, IL, USA). STATA version3;1 7(5):521–528  523
11  was  used for simple and multivariate modeling. Descrip-
tive  statistical methods were  used to generate frequencies
for  categorical variables and to summarize frequencies using
graphical  methods. Negative binomial logistic regression anal-
ysis was  used to investigate the effect of selected risk factors
on  treatment success. Although logistic regression is the
commonly  used method to model binary outcome variable,
odds  ratio obtained from logistic regression is more  likely to
overestimate  the true relative risk. Hence, we  have reported
incidence rate ratio and its corresponding 95% conﬁdence
interval, which was  generated from negative binomial logistic
regression.  In this study any speciﬁc variable was  not hypoth-
esized  as the main risk factor for treatment success. Hence,
patient  age, sex, treatment center, year of treatment initiation
and  baseline smear result of the patient were  all considered in
univariate and multivariate negative binomial logistic regres-
sion.  Moreover, the effect of treatment category of the patient
while  starting treatment and sputum smear result at the 2nd,
5th,  and 7th month of treatment on treatment success were
investigated in bivariate negative binomial logistic regression.
Results  were reported as being statistically signiﬁcant if p-
value  was  less than 5%.
Ethical  considerations
Ethical clearance for the conduct of this study was  obtained
from  the Institutional Research Ethics Review Board of Aklilu
Lemma  Institute of Pathobiology, College of Health Sciences,
Addis  Ababa University (ALIPB AAU) and Addis Ababa City
Administration Health Bureau with registration number of
AAHB/3088/451. After this approval, the three Sub-cities
health ofﬁces approved the study. In order to ensure conﬁden-
tiality  of the information, names or identiﬁcation numbers of
TB  patients were not included in the data sheet.
Result
Demographic  and  clinical  characteristics  of  study
participants
A total of 6450 (100%) registered TB patients were  included
in  this study, with 3017 (46.8%) patients being male. These
patients  had a mean, standard deviation and median age of
30.1,  13.7 and 28.0 years, respectively. In total, 1652 (25.6%)
were  pulmonary positive, 2187 (33.9%) were  pulmonary neg-
ative,  and 2611 (40.5%) were extra-pulmonary TB patients. In
terms of treatment categories 5736 (88.9%) were  new and 160
(2.5%)  were  relapse TB patients (Table 1).
Acid  fast  staining  result  of  registered  TB  patients  during
treatment
Of the 1641 (25.4%) pulmonary positive TB patients, 1376
(83.9%)  had AFB staining laboratory examination at the 2nd
month  of treatment. From these 1376 (100%) patients 49 (0.8%)
were  AFB positive. In addition 1193 (72.7%) of pulmonary pos-
itive  TB patients had AFB staining examination at the 5th
month  with 24 (0.4%) being positive. At the 7th month 19 (0.3%)
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Table 1 – Characteristics of registered TB patients in Addis Ababa, Ethiopia, March 2010.
Variables Type of TB Total number of TB
patients  n (%)
Pulmonary positive n (%) Pulmonary negative n (%) Extra pulmonary n (%)
Sex
Male 717 (23.8) 988 (32.7) 1312 (43.5) 3017 (47)
Female 935 (27.2) 1199 (34.9) 1299 (37.8) 3433 (53)
Age categories
0–14 58 (12.6) 168 (36.6) 233 (50.8) 459 (7.1)
15–24 583 (30.2) 551 (28.5) 798 (41.3) 1932 (30.0)
25–34 534 (26.4) 689 (34.1) 800 (39.5) 2023 (31.4)
35–44 253 (23.7) 390 (36.5) 426 (39.9) 1069 (16.6)
45–54 136 (25.3) 200 (37.2) 201 (37.4) 537 (8.3)
55–64 50 (19.9) 111 (44.2) 90 (35.9) 251 (3.9)
≥65 38 (21.2) 78 (43.6) 63 (35.2) 179 (2.8)
Treatment center
Teklehaimanot HC 808 (26.9) 1259 (41.9) 935 (31.1) 3002 (46.5)
Selam HC 269 (25.0) 373 (34.6) 436 (40.4) 1078 (16.7)
Kolfe HC 575  (24.3) 555 (23.4) 1240 (52.3) 2370 (36.7)
TB patients category
New  1450 (25.3) 1907 (33.2) 2379 (41.5) 5736 (88.9)
Relapse 134 (83.8) 14 (8.8) 12 (7.5) 160 (2.5)
Failure 4 (30.8) 5 (38.5) 4 (30.8) 13 (0.2)
Default 6 (50.0) 2 (16.7) 4 (33.3) 12 (0.2)
Transfer in 40 (24.4) 45 (27.4) 79 (48.2) 164 (2.5)
14 (58
87 (33Others 18 (4.9) 2
Total 1652 (25.6) 21
were  AFB staining positive out of 1052 (63.6%) pulmonary pos-
itive  TB patients.
Treatment  outcomes
A detailed summary of treatment outcomes of the study par-
ticipants  is presented in Table 2. A total of 6450 tuberculosis
patients were  analyzed: 1167 (18%) cured, 4164 (64.6%) com-
pleted  treatment, 2.36 (3.7%) died, 26 (0.4%) were treatment
failure, 328 (5.1) defaulted, and 351 (5.4) transferred out. The
rates  of treatment completion and death were 810 (65.9) and
51  (4.1) in July 2004–June 2005 to 622 (69.7) and 37 (4.1) in July
2008–June  2009. In the same line, defaulting rate decreased
drastically from 107 (8.7%) in July 2004–June 2005 to 17 (1.9%)
in  July 2008–June 2009.
Treatment  success  rate
Between July 2004 and June 2009 the mean treatment suc-
cess  of all registered TB patients was  82.7% without signiﬁcant
gender  effect (84.4% among males and 81.4% among females;
p-value  > 0.05). The treatment success was  81.4% among pul-
monary  positive patients, 83.3% among pulmonary negative
patients,  and 83.1% among extra pulmonary TB patients.
Trend  analysis  over  time:  between  July  2004  and  June
2009The proportions of smear-positive pulmonary TB (PTB+)
patients were  less than 30% per year. The proportion of smear-
negative  pulmonary TB and extra pulmonary TB increased.6) 133 (36.4) 365 (5.6)
.9) 2611 (40.5) 6450 (100)
from  2007 onwards whereas smear-positive pulmonary TG
had  a slight decrement. The trend of treatment success across
the  years for registered TB patients from July 2004 to June 2009
showed  a rise in treatment success rates from 2004 onwards.
Again,  unsatisfactory TB treatment outcomes (died, failed, and
defaulted)  across 2004–2009 showed a rise in the rate of death
from  2008 onwards and reduction of defaulting rate.
Factors  associated  with  treatment  success
Results from negative binomial logistic regression taking
treatment success as an outcome of interest is summarized
in  Table 3.
After  adjusting for pre-speciﬁed selected risk factors
patients were  less likely to have treatment success if they
were  treated in Selam health center (adjusted IRR = 0.76;
95%CI:  (0.69–0.83) or Kolfe health center (adjusted IRR = 0.88;
95%CI:  (0.82–0.95) compared to patients treated in Teklehay-
manot  health center. Although the statistical signiﬁcance was
marginal  patients registered into DOTS program between July
2004 and June 2005 were  more  likely to have treatment suc-
cess  compared to patients registered into the DOTS program
between  July 2005 and June 2006 (Table 3).
Discussion
In this health institution based historical cohort study infor-
mation  was  extracted from documents of 6450 registered TB
patients;  53.2% of the patients were  females. In contrary to
this  study, previous study in southern Ethiopia documented
relatively small proportion of female patients registered for TB
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Table 2 – Treatment outcomes of registered TB patients in Addis Ababa, Ethiopia, March 2010.
Variables Treatment outcome Total
Cured n (%) Treatment
completed n (%)
Died n (%) Treatment
failure n (%)
Default  n (%) Transferred
out  n (%)
TB patients category
New  1038 (18.1) 3713 (64.7) 200 (3.5) 13 (0.2) 293 (5.1) 479 (8.3) 5736 (88.9)
Relapse 92 (57.5) 37 (23.1) 4 (2.5) 8 (5.0) 11 (6.9) 8 (5.0) 160 (2.5)
Failure 1 (7.7) 6 (46.2) 1 (7.7) 2 (15.4) 1 (7.7) 2 (15.4) 13 (0.2)
Return after default 4 (33.3) 6 (50.0) 0 (0) 1 (8.3) 0 (0) 1 (8.3) 12 (0.2)
Transfer in 21 (12.8) 101 (61.6) 17 (10.4) 2 (1.2) 8 (4.9) 15 (9.1) 164 (2.5)
Others 11 (3.0) 301 (82.5) 14 (3.8) 0 (0) 15 (4.1) 24 (6.6) 365 (5.6)
Type of TB
Pul.  positive 1071 (64.8) 274 (16.6) 45 (2.7) 22 (1.3) 100 (6.1) 140 (8.5) 1652 (25.6)
Pul. negative 48 (2.2) 1767 (80.8) 79 (3.6) 1 (0) 117 (5.3) 175 (8.0) 2187 (40.0)
Extra pulmonary 48 (1.8) 2123 (81.3) 112 (4.3) 3 (0.1) 111 (4.3) 214 (8.2) 2611 (40.1)
Age category
0–14  46 (10.0) 346 (75.4) 16 (3.5) 1 (0.2) 17 (3.7) 33 (7.2) 459 (7.1)
15–24 415 (21.5) 1227 (63.5) 35 (1.8) 10 (0.5) 79 (4.1) 166 (8.6) 1932 (30.0)
25–34 385 (19.0) 1302 (64.4) 75 (3.7) 11 (0.5) 101 (5.0) 149 (7.4) 2023 (31.4)
35–44 169 (15.8) 694 (64.9) 48  (4.5) 4 (0.4) 67 (6.3) 87 (8.1) 1069 (16.6)
45–54 91 (16.9) 314 (58.5) 36  (6.7) 0 (0) 38 (7.1) 58 (10.8) 537 (8.3)
55–64 34 (13.5) 165 (65.7) 14 (5.6) 0 (0) 15 (6.0) 23 (9.1) 251 (3.9)
≥65 27 (15.1) 116 (64.8) 12 (6.7) 0 (0) 11 (6.1) 13 (7.3) 179 (2.8)
Treatment center
Teklehaimanot HC 596 (19.9) 2085 (69.5) 16 (0.5) 6 (0.2) 116 (3.9) 183 (6.0) 3002 (46.5)
Selam HC 161 (14.9) 578 (53.6) 42 (3.9) 1 (0.1) 108 (10) 188 (17.4) 1078 (16.7)
Kolfe HC 410 (17.3) 1501 (63.3) 178 (7.5) 19 (0.8) 104 (4.4) 158 (6.7) 2370 (36.7)
Sex of the patients
Male  533 (17.7) 2003 (66.4) 101 (3.3) 10 (0.3) 137 (4.5) 233 (7.7) 3017 (46.8)
Female 634 (18.5) 2161 (62.9) 135 (3.9) 16 (0.5) 191 (5.6) 296 (8.6) 3433 (53.2)
Year of treatment
July  2004–June 2005 154 (12.5) 810 (65.9) 51 (4.1) 7 (0.6) 107 (8.7) 100 (8.1) 1229 (19.0)
July 2005–June 2006 255 (17.7) 811 (56.4) 48 (3.3) 2 (0.1) 131 (9.1) 191 (13.3) 1438 (22.3)
July 2006–June 2007 335 (21.9) 1013 (66.3) 53 (3.5) 7 (0.5) 24 (1.6) 97 (6.3) 1529 (23.7)
July 2007–June 2008 266 (19.5) 908 (66.7) 47 (3.5) 6 (0.4) 49 (3.6) 86 (6.3) 1362 (21.1)
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nJuly 2008–June 2009 157 (17.6) 622 (69.7) 37 (4.
Total 1167 (18) 4164 (64.6) 236 (3.
reatment and an exceptionally lower proportion of patients
lder  than 45 years of age.16 In agreement with the previous
tudy  conducted in South Ethiopia,20 78% of the registered
B  patients in this study were  from the productive age
roup.15–32 This may  indicate negative impact of TB on the
ocio-economic condition of the society. In this study extra
ulmonary  TB patients constituted the prevailing form of
B.  Extra pulmonary TB is more  common in patients with
IV  infection.21,22 Overall, treatment success of registered TB
atients  in this study was  82.7% which is very high com-
ared  to previous ﬁnding in South Ethiopia20 and in Gonder
niversity Teaching hospitals.16 Possible elucidations for the
bserved  difference between the ﬁndings of this study and
he  previous two Ethiopian studies might be explained by high
ransfer out in the study of Gonder University hospital16 and
ncreased  number of unrecorded treatment outcome in the
tudy  in South Ethiopia.20 The overall treatment success rate
n  this study was  higher than rates reported by studies con-
ucted  in Gondar University Teaching Hospital, Northwest
thiopia16 and in the Southern Ethiopia20 and from the 66%
uccessful treatment outcome in Thailand.23 However, it was
early  similar to the ﬁnding of other two studies in southern4 (0.4) 17 (1.9) 55 (6.1) 892 (13.8)
26 (0.4) 328 (5.1) 351 (5.4) 6450
Ethiopia.24,25 It also substantiates the average treatment suc-
cess  (83%) rate of 22 high burden countries.26
In the current study the treatment success rate was
84.4% for male pulmonary TB patients and 81.4% for female
pulmonary TB patients. Contrary to this ﬁnding, in South
Ethiopia female smear-positive pulmonary TB (PTB+) patients
had  signiﬁcantly higher treatment success (58% versus 54%;
p-value  = 0.001)16 which might be showing the actual circum-
stances  of gender difference in the TB epidemiology in the
study  area.27,28
The observed progress in the trend of treatment success
from  2006 through 2009 in the current study was similar to
the  ﬁndings of the study in South Ethiopia, in which treatment
success  for smear-positive TB increased from 38% in 1994 to
56%  in 1998, 70% in 1999 and 73% in 2000.20 This progress
may  be partly explained by the improvement in the diagnosis
of  the diseases and partly by the practice of using triple and
double  FDC drugs which might have provided advantages to
29,30supporting adherence and program delivery. In agreement
with  the previous study in southern Ethiopia20 different treat-
ment  success rates among treatment centers were  noted in
this study. After adjusting for potential confounding variables
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Table 3 – Negative binomial logistic regression analysis having treatment success as the outcome of interest. Addis
Ababa, Ethiopia, March 2010.
Characteristics Total number (%) of TB
cases  examined
Number  (%) with
treatment
success
Crude incident
rate  ratio (95% CI)
Adjusted
incident  rate
ratio  (95% CI)
Age
0–14 459 (7.1) 392 (85.4) 1.0 1.00
15–24 1932 (29.9) 1642 (85.0) 1.00 (0.89, 1.11) 1.01 (0.90, 1.12)
25–34 2023 (31.4) 1687  (83.4) 0.98 (0.87, 1.09) 0.98 (0.88, 1.10)
35–44 1069 (16.6) 863  (80.7) 0.95 (0.84, 1.07) 0.95 (0.84, 1.07)
45–54 537 (8.3) 405 (75.4) 0.88 (0.77, 1.01) 0.89 (0.77, 1.02)
55–64 251 (3.9) 199 (79.3) 0.93 (0.78, 1.10) 0.92 (0.78, 1.09)
≥65 179 (2.8) 143 (79.9) 0.94 (0.77, 1.13) 0.93 (0.77, 1.13)
Treatment center
Teklehaimont HC 3002 (46.5) 2681 (89.3) 1.0 1.00
Selam HC 1078 (16.7) 739 (68.6) 0.77 (0.71, 0.83) 0.76 (0.69, 0.83)
Kolfe HC 2370 (36.7) 1911 (80.6) 0.90 (0.85, 0.96) 0.88 (0.82, 0.95)
Year of treatment
July  2004–June 2005 424 (6.6) 358 (84.4) 1.00 1.00
July 2005–June 2006 1492 (23.1) 1132 (75.9) 0.90 (0.80, 1.01) 0.89 (0.79, 0.99)
July 2006–June 2007 1661 (25.8) 1330 (80.1) 0.95 (0.84, 1.07) 0.94 (0.84, 1.06)
July 2007–June 2008 1405 (21.8) 1234 (87.8) 1.04 (0.92, 1.17) 1.05 (0.93, 1.18)
July 2008–June 2009 1468 (22.8) 1277 (87.0) 1.03 (0.92, 1.16) 1.04 (0.92, 1.16)
Sex
Male 3017 (46.8) 2536  (84.1) 1.00 1.00
Female 3433 (53.2) 2795 (81.4) 0.97 (0.92, 1.02) 0.97 (0.92, 1.03)
Baseline smear result
Positive  1641 (25.4) 1342 (81.8) 1.00 1.00
Negative 3129 (48.5) 2670 (85.3) 1.04 (0.98, 1.11) 1.02 (0.95, 1.09)
Not done 1680 (26.1) 1319 (78.5) 0.96 (0.89, 1.04) 1.02 (0.94, 1.11)
Treatment category of the patients
New  5736 (88.9) 4751 (82.8) 1.00
Relapse 160 (2.5) 129 (80.6) 0.97 (0.82, 1.16)
Failure 13 (0.2) 7 (53.9) 0.65 (0.31, 1.36)
Default 12 (0.2) 10 (83.3) 1.01 (0.54, 1.87)
Retreatment 164 (2.5) 122 (74.4) 0.90 (0.75, 1.07)
Other 365 (5.7) 312 (85.5) 1.03 (0.92, 1.16)
Sputum smear results at 2nd month
Positive  49 (0.8) 36 (73.5) 1.00
Negative 1327 (20.6) 1171 (88.2) 1.20 (0.86, 1.67)
Not done 5074 (78.7) 4124 (81.3) 1.11 (0.80, 1.54)
Sputum smear results at 5th month
Positive 24  (0.4) 17 (70.8) 1.00
Negative 1169 (18.1) 1067 (91.3) 1.29 (0.80, 2.08)
Not done 5257 (81.5) 4247 (80.8) 1.14 (0.71, 1.84)
Sputum smear results at 7th month
Positive  19 (0.3) 13 (68.4) 1.00
942 (
376 (Negative 1033 (16.0) 
Not done 5398 (83.7) 4
patients treated in Teklehaymanot health center had the best
treatment success rate compared with patients treated in
Selam  or Kolfe health centers. This might be explained by the
heterogeneity  of service provision among health centers. For
example, the quality of follow up of patients on anti-TB treat-
ment  under DOTS might be better in Teklehaymanot health
center  resulting in increased likelihood of better treatment
outcome. Some evidence shows that human resources for
health  (HRH) in TB control is unsatisfactory and there is a sig-
niﬁcant  variability in workload and productivity of staff within
and  between countries31 as well major factors contributing91.2) 1.33 (0.77, 2.30)
81.1) 1.18 (0.69, 2.04)
to  this are patient load, organization of services and Human
Resource  Management activities, all will be different in differ-
ent  settings.32
Like any other study based on secondary data analysis the
current  study has strengths as well as limitations which need
to  be noted while interpreting the ﬁndings. The main strength
of  the study is that it was  conducted at health centers that
represent different level of potential health service coverage
in  Addis Ababa. Hence, the ﬁnding can clearly reﬂect the treat-
ment  outcome of TB patients under DOTS program at the
primary  health care level in Addis Ababa. One of the major
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imitations was  that information on co-infection with HIV was
ot  collected and adjusted for. Additionally, the duration of
egimen  has been changed from 12 months to 9 months then
o  six months during the study years. However, the health cen-
ers did not change treatment regimen at the same time hence
t  was  difﬁcult to compare the effect treatment regimens. The
istorical  data used in this paper was  originally collected pri-
arily  for reporting purposes. The weakness of this type of
ata  is well known, especially, in low income countries, where
he  quality of reports are often poor.11
onclusion
he mean treatment success rate of all registered pulmonary
B  patients was  82.6% and it was  not signiﬁcantly affected
y  gender, age and type of TB. However, year of treatment
nd  treatment center were  signiﬁcantly associated with treat-
ent  success. During the study period there was  signiﬁcant
umber of lost to follow-up. Based on this ﬁnding it is recom-
ended  to implement frequent supportive supervision during
he  course of treatment, strengthen referral linkage among
acilities,  and conduct further research to ﬁnd out the reasons
or  the observed difference among the DOTS services across
reatment  centers.
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